VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen
The anti-CSPG4 monoclonal antibodies (mAbs) have shown anti-tumor activity and therapeutic potential for treating breast cancer. In addition, CSPG4 is a dominant tumor-associated antigen that is also involved in normal-tissue development in humans. Therefore, the potential for off-tumor activity rem...
Main Authors: | Bernice Nounamo, Fariba Jousheghany, Eric Robb Siegel, Steven R. Post, Thomas Kelly, Soldano Ferrone, Thomas Kieber-Emmons, Behjatolah Monzavi-Karbassi |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-01-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/24/3/2506 |
Similar Items
-
Tumor-Associated Glycans and Immune Surveillance
by: Anastas Pashov, et al.
Published: (2013-06-01) -
Chondroitin Sulphate Proteoglycan 4 (NG2/CSPG4) Localization in Low- and High-Grade Gliomas
by: Marta Mellai, et al.
Published: (2020-06-01) -
Harnessing benefit from targeting tumor associated carbohydrate antigens
by: Thomas Kieber-Emmons, et al.
Published: (2017-02-01) -
Decitabine-Mediated Upregulation of CSPG4 in Ovarian Carcinoma Cells Enables Targeting by CSPG4-Specific CAR-T Cells
by: Dennis Christoph Harrer, et al.
Published: (2022-10-01) -
A Novel Antibody-Drug Conjugate (ADC) Delivering a DNA Mono-Alkylating Payload to Chondroitin Sulfate Proteoglycan (CSPG4)-Expressing Melanoma
by: Ricarda M. Hoffmann, et al.
Published: (2020-04-01)